Amgen bought deCODE genetics for US$415 million in December 2012, with a plan to ramp up their use of human genetic data in drug discovery and development. This deal has since transformed Amgen's pipeline, says Amgen Chief Scientific Officer Sean Harper. A treasure trove of genetic data from more than 160,000 Icelanders now informs everything from target selection to clinical trial design. Genetic insights, sequencing capabilities and analytical expertise have helped the company to avoid costly failures, prosecute programmes more effectively and discover de novo drug targets, he told Asher Mullard.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Sean Harper. Nat Rev Drug Discov 17, 10–11 (2018). https://doi.org/10.1038/nrd.2017.262
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd.2017.262
